Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
BiomX (PHGE) announced a financial update for Q2 2021, highlighting a cash balance of $47.3 million, enabling operations until mid-2023. The company completed a $15 million equity raise and secured a $30 million debt agreement. Four clinical data readouts are expected by mid-2022, including Phase 2 results for acne treatment BX001 due in October. R&D expenses increased to $3.8 million, with a net loss of $7.3 million for the quarter. Upcoming milestones include trials for atopic dermatitis and cystic fibrosis therapies.
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.
BiomX (NYSE American: PHGE) has announced a registered direct offering of 3,750,000 shares and warrants for a total expected gross of $15 million. The offering price is set at $4.00 per share, with warrants exercisable for 0.75 shares at $5.00 each, expiring in five years. The proceeds will support clinical trials and general corporate purposes. The closing date is anticipated around July 28, 2021, pending customary conditions. The offering follows an effective shelf registration statement declared by the SEC in December 2020.
BiomX Inc. (PHGE) announced promising preclinical results for its phage therapy candidate, BX005, targeting Staphylococcus aureus in atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, the results indicate BX005 efficiently eradicates harmful bacteria without mutant strain emergence. CEO Jonathan Solomon emphasized its potential for safer, effective treatment options, especially for children. BiomX expects to share Phase 2 safety and efficacy results in early 2022. The conference presentations occurred on June 13 and will continue on June 17-18, 2021.
BiomX (PHGE) announced promising preclinical results for BX004, a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. Presented at the 44th European Cystic Fibrosis Conference, the data demonstrated BX004's effectiveness in reducing bacterial levels encased in biofilm, outperforming two antibiotics. Following these results, BiomX plans to advance BX004 to a Phase 1b/2a trial, with outcomes from Part 1 expected in Q1 2022. This advancement indicates the company's commitment to innovative therapies addressing chronic diseases.
BiomX (PHGE) reported Q1 2021 financial results, highlighting progress in clinical trials for its phage therapies. The company completed enrollment of 140 patients in a Phase 2 study of BX001 for acne, with results expected in Q3 and Q4. Positive safety data from BX002 for Inflammatory Bowel Disease prompted a transition to a Phase 1b/2a trial for BX003. Cash on hand was $53.6 million, supporting operations into mid-2022. R&D expenses increased to $5.8 million, and the net loss rose to $8.4 million, compared to $5.9 million in Q1 2020.
BiomX Inc. (PHGE) will host a virtual key opinion leader webinar on May 26, 2021, at 8:00 AM EDT, focusing on BX003, a phage therapy targeting Klebsiella pneumoniae for inflammatory bowel disease (IBD). Dr. Ryan Balfour Sartor, a leading expert, will discuss the efficacy of microbiome-based treatments. Following a successful Phase 1a study, BiomX aims to enter Phase 1b/2a trials evaluating BX003's safety and efficacy, with results expected by Q2 2022. Registration is available on BiomX's investor website.
BiomX Inc. (PHGE) announced a conference call on May 24, 2021, at 8:00 a.m. EDT to report its first quarter 2021 financial results and provide updates on business progress. The call will be accessible via phone and webcast on the Company’s website. BiomX is focused on developing natural and engineered phage therapies to combat specific pathogenic bacteria impacting skin health and chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at two virtual investor events in April 2021. The first is the Jefferies Microbiome-Based Therapeutics Summit on April 22, available on-demand from 8:00 AM EDT. The second is the Ladenburg Thalmann R&D Showcase on April 29 at 1:00 PM EDT, where Solomon will discuss the acne landscape and the lead product candidate, BX001, alongside Dr. Leon Kircik. Webcasts can be accessed on the company’s website.
BiomX (NYSE American: PHGE) reported its fourth quarter and full year financial results for 2020, highlighting significant advancements in its pipeline, including new phage cocktail candidates BX004 and BX005 targeting cystic fibrosis and atopic dermatitis. The company anticipates key efficacy data from two Phase 2 studies in 2021. Financially, BiomX ended 2020 with a cash balance of $57.1 million, down from $82.4 million in 2019, primarily due to increased operational costs. The net loss for the year increased to $30.1 million from $20.6 million in the prior year.